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INTRODUCTION
HMGB1 is an DNA-binding nucleotide protein 
whose primary function is as a factor of transcrip-
tional regulation and growth.1,2 HMGB1 as a co-factor 
nuclear acting as an intracellular messenger molecule, 
is released to extracellular cells when injured or 
infected.3,4 Another role of HMGB1 is pro-inflamma-
tory cytokines that contribute significantly in many 
cases of inflammation and sepsis. HMGB1 interacts 
with toll-like receptors (TLR4) to release macrophage 
cytokines.5,6 Lidocaine have analgesic and anti-arrhytmic 
effects, also have anti- inflammatory properties and 
cascade inflammation modulating effect on model 
sepsis mice induced with lipopolysaccharide.7,8,9 Previous 
studies have shown that administration of systemic 
lidocaine can inhibits HMGB1 mRNA expression and 
provides a protective effect against liver, lung and 
cardiac ischemia in model sepsis mice.10 The purpose 
of this study was to determine whether the administra-
tion of systemic lidocaine dose 2 mg/kgBW for 24 h 
can inhibit expression of HMGB1 mRNA and TLR4 
protein level in BALB/c mice who suffered sterile 
injury.
MATERIAL AND METHODS
This research is animal trial prospective laboratory study 
using healthy male BALB/c mice (weight 35-40 grams, 
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age 10-12 weeks; n = 20). Healthy BALB/c mice have 
glowing eyes, no dull feathers, active moves, and a 
good appetite. Mice that died during the study were 
excluded. Mice were obtained from the unit main-
tenance and development of animal trial Molecular 
Microbiology Laboratory and Immunology Faculty 
of Medicine, Hasanuddin University, Makassar, 
Indonesia. The mice were adapted and treated the 
following procedures and principles of the Declara-
tion of Helskinki. BALB/c mice were divided into 
two groups: lidocaine group and control group, 
each group consist 10 mice. At first, blood from the 
tail vein each mouse was taken as much as 0.3 ml 
to examine the expression of HMGB1 mRNA and 
TLR4 protein in first blood, mice then in anesthe-
tized with ketamine 50 mg/kgBW intraperitoneally. 
Sterile injury is done by closed fracturing the left 
thigh bone of the mice using two needle holders. 
Four hours after the mice had a sterile injury, 0.3 ml 
blood was taken again from tail vein for a second 
blood examination. The lidocaine group was given 
therapy with 2 mg/kgBW of lidocaine (2 % lidocaine, 
PT Kimia Farma, Jakarta, Indonesia) through tail 
vein injection, once every 2 h, continuously until 24 
h. The control group was given distilled water as a 
replacement for lidocaine therapy. Two hours after 
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the treatment of lidocaine and distilled water were completed, 0.3 ml 
of blood was drawn again from the two study groups for a third blood 
test. All blood samples were mixed with L6 solution and processed into 
nucleic acid extract and stored at -80°C before the qPCR and ELISA were 
examined.
ELISA Assay
The level of TLR4 protein in the serum and was determined with ELISA 
kits (Life Span Bioscience, Inc. of Seattle, North America) according to 
the manufacturer’s instructions.
Quantitative Real-time polymerase chain reaction 
(qPCR) Analysis
The qPCR examination was performed using a PCR Bio-Rad 
BR004129USA machine. A mixture of 22.5 μl PCR Mastermix and 
SYBR reen QRT was prepared. The following forward and reverse primers 
(1µl each) for HMGB1, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as housekeeping gene, were used: (HMGB1 for, GAG ATC 
CTA AGA AGC CGA GA; HMGB1 Rev, CTT CCT CAT CCT CCT 
ATC; GAPDH for, GAC CAC AGT CCA TGC CAT CA; GAPDH Rev, 
CAT CAC BCC ACA CTT TCC). Next, 2.5 μl of DNA extract was added 
to the 22.5 μl mixture of primary PCR mix + primary. First stage ampli-
fication was performed at 94°C for 2 s and continued until 40 cycles 60 s 
at 94°C, and 45 s at 57°C. Then, the results come out in the form of data.
Statistical analysis
The data were processed using SPSS software version 20. The normally 
distributed data were compared with a Kolmogorov-Smirnov test and 
presented as mean ± SD. Comparison of data between groups were made 
using a t- test. A value of p < 0.05 was considered significant.
Ethics statement
The study was conducted after obtaining a recommendation letter of 
ethical clearance from the Medical Research Ethics Committee at the 
Faculty of Medicine, Hasanuddin University (Makassar, Indonesia) with 
registration number UH16050436 dated October 28, 2016.
RESULTS
The average weight of BALB/c mice in the lidocaine group was 41.3 
grams and in the control group of 39.34 grams. There was no significant 
difference between the two experimental groups p < 0.05.
i. Control group:
The initial HMGB1 mRNA expression mean ± SD was 6.75 ± 0.36, 
after 4 h of sterile injury increased to 11.29 ± 0.64 and 2 h after 
distilled water administration increased steadily to 13.49 ± 0.45. 
The HMGB1 mRNA expression increase significantly, p value < 
0.00. Preliminary TLR4 protein content of mean ± SD is 0.31 ± 
0.18, after 4 hours of sterile injury increased to 1.67 ± 0.26 and 2 h 
after distilled water administration increased to 2.65 ± 0.28. TLR4 
protein level increase significantly, p value < 0.00.
The HMGB1 mRNA expression and TLR4 protein levels in both 
control groups can be seen in Figure 1.
ii. Lidocaine group: 
The initial expression of the mean HMGB1 mRNA ± SD was 6.73 
± 0.66, after 4 h of sterile injury increased to 11.90 ± 0.62 and 2 
h after lidocaine therapy decreased to 6.94 ± 0.51. The mRNA 
HMGB1 expression decreases significantly, p value < 0.00. 
Preliminary TLR4 protein content of mean ± SD is 0.30 ± 0.13, 
after 4 h of sterile injury increased to 1.83 ± 0.24 and 2 h after 
lidocaine therapy decreased to 0.56 ± 0.17. Protein level TLR4 
decreases significantly, p value < 0.00.
The HMGB1 mRNA expression and TLR4 protein levels in both groups 
of lidocaine can be seen in Figure 2.
DISCUSSION
HMGB1 is a non-histone nuclear protein abundant and can be found in 
almost all types of mammalian cells.11 HMGB1 includes a classic pro-
inflammatory cytokine mediator, HMGB1 level will increase in blood 
in the event of injury or infection.12 HMGB1 is released passively from 
necrotic cells and actively from macrophage, monocyte, and dendritic 
cells.13 Excessive increased level of HMGB1 is always associated with 
worsening organ function. Extracellular HMGB1 will activate the signal 
path of TLR4 cell macrophages and dendrites.14,15
Figure 1: An expression of HMGB1 mRNA and TLR4 protein levels in 
both control groups
Figure 2: An expression of HMGB1 mRNA and TLR4 protein levels in 
both groups of lidocaine
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Our results show that HMGB1 mRNA expression and TLR4 protein 
levels can be found in normal BALB/c mice blood. The expression of 
HMGB1 mRNA and TLR4 protein content increased after 4 h of BALB/c 
mice since sterile injury. Increase of mRNA HMGB1 expression and 
protein TLR4 shows that sterile injury within mice BALB/c results in 
severe inflammation. Control group express mRNA HMGB1 and TLR4 
protein level statistically significant, p < 0.00. Result of this study shows 
that sterile aquadestila injection does not have therapeutical effect to 
inhibit inflammation. 
The expression of mRNA HMGB1 in lidocaine group increased 1.8 times, 
from mean ± SD: 6.73 ± 0.66 to 11.90 ± 0.62, and TLR4 protein level 
increased 6.2 times from mean ± SD: 0.30 ± 0.13 to 1.83 ± 0.24. Increased 
expression of HMGB1 mRNA and TLR4 protein levels in the lidocaine 
group decreased after lidocaine therapy 2 mg/kgBW every 2 h, continuously 
for 24 h, each from mean ± SD: 11.90 ± 0.62 to 6.94 ± 0.51 and from 
mean ± SD: 1.83 ± 0.24 to 0.56 ± 0.17. decreased expression of mRNA 
HMGB1 and protein TLR4 is significant in statistic, p value < 0.00. Our 
results show that 2 mg/kgBW lidocaine administration inhibits transcrip-
tion of HMGB1 mRNA expression and translation of TLR4 protein in 
sterile injury BALB/c mice with sterile injury.16,17 Previously, Hollmann 
MW et al have shown that amide groups local anesthesia inhibited 
release of inflammatory mediators leukotrin B4 and interleukin-1 from 
human neutrophils and monocytes.8 
In a previous reasearch, Wang HL et al demonstrated that administration of 
systemic lidocaine inhibits release of HMGB1 septic mice which induced 
with lypopolysaccharide 10 and transcription of mRNA HMGB1 in 
patients during histerectomy.18 In a separate study, Liu J et al have shows 
that systemic lidocaine therapy protects dysfunction of kidney and liver 
in septic mice model with inhibiting expression of TLR4, NF-κβ and 
interleukin-6.19 
While the expression of HMGB1 mRNA and TLR4 protein levels in the 
control group increased steadily when compared from before the injury, 
4 h after injury, and 2 h after administration of distilled water, p < 0.00. 
The results of this study show that administration of distilled water does 
not provide a therapeutic efficacy to inhibit inflammatory process.
The results of this study are consistent with the results of previous studies 
showing that systemic lidocaine therapy has anti-inflammatory properties 
in a number of sepsis disease models in experimental animals.
Within our hypothesis that 2mg/kgBW intravenously administered 
lidocaine every 2 hours, continuously for 24 hours of efficacy is used to 
inhibit transcription of HMGB1 mRNA expression and TLR4 protein 
translation in sterile inflammation.
CONCLUSION
Intravenous administration 2 mg/kgBW of lidocaine therapy every 
2 hours, continuously for 24 hours is effectively used to inhibits HMGB1 
mRNA expression and TLR4 protein in BALB/c mice that sustain inflam-
mation due to a sterile injury. Our results re-emphasize the importance 
of understanding that systemic lidocaine therapy has effect on anti-
inflammatory in many conditioned diseases caused by sterile inflammation 
or infection.
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GRAPHICAL ABSTRACT SUMMARY
High mobility group box 1 (HMGB1) is a cytokine proinflamation which contrib-
utes to inflammation. HMGB1 physically interacts with toll like receptor 4  (TLR4) 
to release macrophage cytokines. Administration systemic 2 mg/kgBW  of lido-
caine is effectively inhibits HMGB1 mRNA and TLR4 protein in mice that sustain 
inflammation due to a sterile injury.
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